Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
|Videos|September 26, 2016
The Impact of Limited Distribution Networks on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses how specialty pharmacies can navigate limited distribution networks.
Advertisement
Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses how specialty pharmacies can navigate limited distribution networks.
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
5